Dual-Energy CT–Based Nomogram for Decoding HER2 Status in Patients With Gastric Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dual-Energy CT–Based Nomogram for Decoding HER2 Status in Patients With Gastric Cancer

Published:2021-06 Issue:6 Volume:216 Page:1539-1548
ISSN:0361-803X
Container-title:American Journal of Roentgenology
language:en
Short-container-title:American Journal of Roentgenology

Author:

Zhao Huiping¹,Li Weiran¹²,Huang Wenpeng¹,Yang Yujiao³,Shen Wei⁴,Liang Pan¹,Gao Jianbo¹

Affiliation:

1. Department of Radiology, The First Affiliated Hospital of Zhengzhou University, No. 1, East Jianshe Rd, Zhengzhou 450052, Henan Province, China

2. Present address: Department of Radiology, Jiangxi Provincial People's Hospital, Nanchang, Jiangxi Province, China

3. Department of Radiology, The Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, Hunan Province, China

4. Hangzhou YITU Healthcare Technology Co., Ltd., Hangzhou, Zhejiang Province, China

Publisher

American Roentgen Ray Society

Subject

Radiology Nuclear Medicine and imaging,General Medicine

Link

https://www.ajronline.org/doi/pdf/10.2214/AJR.20.23528

Reference33 articles.

1. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017

2. The role of HER2 in cancer therapy and targeted drug delivery

3. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

4. Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial

5. Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction of HER2 Expression in Gastric Adenocarcinoma Based On Preoperative Noninvasive Multimodal 18F-FDG PET/CT Imaging;Academic Radiology;2024-08

2. Differentiating between benign and malignant breast lesions using dual-energy CT-based model: development and validation;Insights into Imaging;2024-07-10

3. Predicting human epidermal growth factor receptor 2 status of patients with gastric cancer by computed tomography and clinical features;Gastroenterology Report;2023-12-22

4. Dual-energy CT: A new frontier in oncology imaging;Meta-Radiology;2023-11

5. Application of spectral CT in diagnosis, classification and prognostic monitoring of gastrointestinal cancers: progress, limitations and prospects;Frontiers in Molecular Biosciences;2023-10-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3